Full Press Release Details
Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology
Paves the Way for Development and Marketing of New Cannabinoid-based Treatment Offerings
for Mild Cognitive Impairment and other
Neurological Conditions
Israel, April 5, 2017 - Therapix Biosciences Ltd. (NASDAQ, TASE: TRPX), a specialty clinical-stage pharmaceutical
company specializing in the development of cannabinoid-based drugs, today announced that it has signed a sublicense agreement
for Yissum Research Development Company of the Hebrew University Ltd.'s nasal drug delivery technology.
the terms of the agreement, Yissum will grant Therapix an exclusive, worldwide, sub-licensable, royalty-bearing license to its
technology for the nasal delivery of cannabinoids.
technology, developed by Professor Elka Touitou from the Institute of Drug Research at the Hebrew University of Jerusalem, facilitates
administration and effective nasal absorption of tetrahydrocannabinol, or THC, the active pharmaceutical ingredient in the drugs
developed by Therapix.
agreement with Yissum paves the way for the development and marketing of new cannabinoid-based treatment offerings for people
suffering from a variety of neurological conditions," said Therapix CEO Dr. Elran Haber. "Compared with standard oral
administration, we expect the nasal delivery technology developed by Professor Touitou and her team at Hebrew University to offer
improved bioavailability, efficacy, and a shorter reaction time for patients."
license agreement with Yissum has the potential to advance Therapix's strategy to develop proprietary cannabinoid delivery technologies
to improve drug administration, including nasal and sublingual delivery methods for THC, with formulations designed to increase
Therapix Biosciences Ltd.
Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists,
focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus,
the company is currently engaged in two internal drug development programs based on repurposing an FDA-approved synthetic cannabinoid
(dronabinol): Joint Pharma, developing THX-TS01 targeted to the treatment of Tourette's syndrome; and BrainBright Pharma,
developing THX-ULD01 targeted to the high value and under-served market of mild cognitive impairments. More information is available
online at www.therapixbio.com.
press release contains forward-looking statements about the Company's expectations, beliefs, and intentions. Forward-looking
statements can be identified by the use of forward-looking words such as "believe", "expect", "intend",
"plan", "may", "should", "could", "might", "seek", "target",
"will", "project", "forecast", "continue" or "anticipate" or their
negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to
historical matters. For example, forward-looking statements are used in this press release when we discuss the potential of the
Yissum licensed technology, our expectation that it will improve bioavailability, efficacy and reaction time and the description
of our technology and its proposed uses. These forward-looking statements involve certain risks and uncertainties, including,
among others, risks that could cause the Company's results to differ materially from those expected by Company management
or otherwise described in or implied by the statements in this press release. Any forward-looking statement in this press release
speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking
statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable
securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading
"Risk Factors" in Therapix Biosciences Ltd.'s Prospectus dated March 22, 2017 filed with the SEC, which is available
on the SEC's website, www.sec.gov.
further details, please contact Noa Katz of Goldfinger Communications at +972-50-863-3162.